Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly in Canada or indirectly through partners in Canada, the United States and South America. Its Dermatology products include Actikerall, Epuris, Ozanex and Vaniqa. Its Hospital Acute Care products include Aggrastat and Brinavess. Its Out-Licensed products include Absorica, ConZip and Lipofen. The Company is also focused on building a portfolio of prescription medicines that serve unmet medical needs. The Company's product pipeline development programs including MOB-015, DTR-001, and CF-101. The Company's subsidiaries include Cipher US Holdings Inc., Cipher US Holdco LLC, and Cipher Pharmaceuticals US LLC.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

Post by nozzpackon Oct 15, 2021 9:18am

224 Views

Post# 34008744

Fair Value of $14 per share at Peer EV/ Ebitda

Current EV/Ebitda multiple is 17.22 times..see link below

All Values in C $.

EV = Market cap plius debt less cash =$51 million.

Annual Ebitda - Q2 X 4 X 1.25 = $4.1 US X 4 x 1.25 = $20.5 in C$.

Fair value Market cap = $20.5 X 17.22 + $19 m cash = $370 million in CAD

Fair value Per share = $370 m / 26.5 m shares = $14 cad

We are grossly under valued..nothing new there..

https://pages.stern.nyu.edu/~adamodar/New_Home_Page/datafile/vebitda.html

<< Previous

Bullboard Posts

Next >>

BlackBerry unveils new cybersecurity assistant